Astrazeneca’s Baxfendy wins US approval as first-in-class hypertension drug

Baxfendy works in a fundamentally different way from current therapies

AstraZeneca launches K+ Connect initiative to strengthen hyperkalemia management

Pan-India multidisciplinary program aims to improve coordinated care for patients with chronic kidney disease and heart failure

FDA advisory panel backs AstraZeneca prostate cancer combo in decisive vote

The Committee backed the combination based on results from the CAPItello-281 Phase III trial, marking a key milestone in the regulatory pathway for AstraZeneca’s targeted therapy strategy in prostate cancer

FDA advisory panel narrowly withholds support for AstraZeneca’s combo in breast cancer

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor

FDA okays AstraZeneca’s triple therapy Breztri for asthma

The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device

AstraZeneca wins US nod for at-home lupus treatment in major shift for SLE care

The approval was driven by data from the Phase III TULIP-SC trial

AstraZeneca backs next-gen cardiologists with India Coronary Conquest 2026

The programme has already drawn over 120 complex percutaneous coronary intervention (PCI) case submissions from across the country

Galderma rolls out next-generation regenerating skin nectar

Transgene and NEC join forces to advance personalized cancer vaccine

TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor

OneCyte and Kemp Proteins to revolutionize cell line development

Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules